Chai Discovery, an artificial intelligence drug-discovery company backed by OpenAI, has raised $130 million to build a “computer-aided design suite” for molecules. The deal, which values the company at $1.3 billion, comes just three months after the startup’s last funding round and brings its total financing to $225 million. The Series B financing was co-led by Oak HC/FT and General Catalyst. “Looking back over the last five to 10 years, there’s been so much hype on AI for drug discovery,” co-founder and Chief Executive Officer Josh Meier said. “This is the year things started working.” The funding follows the release of Chai-2, the company’s latest antibody generation model that can now design molecules for hard-to-tackle diseases.

Full report : AI drug discovery startup Chai Discovery raised a $130 million Series B led by Oak HC/FT and General Catalyst at a $1.3 billion valuation, taking its total funding to $225 million.